Quiros-Roldan E - Search Results

1

Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.

Lapadula G, Calabresi A, Castelnuovo F, Costarelli S, Quiros-Roldan E, Paraninfo G, Ceresoli F, Gargiulo F, Manca N, Carosi G, Torti C. Lapadula G, et al. Antivir Ther. 2008;13(4):601-5. Antivir Ther. 2008. PMID: 18672539

2

HIV-1 pharmacoresistance: clinical and therapeutic implications.

Carosi G, Torti C, Palvarini L, Quiros Roldan E. Carosi G, et al. J Biol Regul Homeost Agents. 1999 Jul-Sep;13(3):163-71. J Biol Regul Homeost Agents. 1999. PMID: 10560750 Review.

3

Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month.

Magalini A, Puoti M, Putzolu V, Quiros-Roldan E, Forleo MA, Rossi S, Zaltron S, Spinetti A, Zanini B, Zonaro A, Solfrini R, Carosi G. Magalini A, et al. J Clin Lab Anal. 2000;14(3):120-4. doi: 10.1002/(sici)1098-2825(2000)14:3<120::aid-jcla6>3.0.co;2-#. J Clin Lab Anal. 2000. PMID: 10797610 Free PMC article. Clinical Trial.

4

Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment.

Puoti M, Gargiulo F, Quiros Roldan E, Chiodera A, Palvarini L, Spinetti A, Zaltron S, Putzolu V, Zanini B, Favilli F, Turano A, Carosi G. Puoti M, et al. J Infect Dis. 2000 Jun;181(6):2033-6. doi: 10.1086/315529. Epub 2000 May 31. J Infect Dis. 2000. PMID: 10837187

5

Mortality for liver disease in patients with HIV infection: a cohort study.

Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, Quiros-Roldan E, Zanini B, Casari S, Carosi G. Puoti M, et al. J Acquir Immune Defic Syndr. 2000 Jul 1;24(3):211-7. doi: 10.1097/00126334-200007010-00003. J Acquir Immune Defic Syndr. 2000. PMID: 10969344

6

Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy.

Quiros-Roldan E, Signorini S, Castelli F, Torti C, Patroni A, Airoldi M, Carosi G. Quiros-Roldan E, et al. J Clin Lab Anal. 2001;15(1):43-6. doi: 10.1002/1098-2825(2001)15:1<43::aid-jcla9>3.0.co;2-i. J Clin Lab Anal. 2001. PMID: 11170234 Free PMC article.

7

Long-term benefit of genotypic-guided therapy and prevalence of multinucleoside resistance in an Italian group of antiretroviral multiexperienced patients.

Quiros-Roldan E, Moretti F, Airoldi M, Fausti C, Chiodera A, Castelli F, Carosi G. Quiros-Roldan E, et al. J Clin Lab Anal. 2001;15(3):127-30. doi: 10.1002/jcla.1015. J Clin Lab Anal. 2001. PMID: 11344527 Free PMC article.

8

Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone.

Puoti M, Cadeo GP, Putzolu V, Forleo MA, Barni MC, Cristini G, Rossi S, Spinetti A, Zaltron S, Zanini B, Quiros-Roldan E, Paraninfo G, Gargiulo F, Carosi G. Puoti M, et al. Dig Liver Dis. 2001 Mar;33(2):163-72. doi: 10.1016/s1590-8658(01)80073-6. Dig Liver Dis. 2001. PMID: 11346146 Clinical Trial.

9

HIV-1 multi-dideoxynucleoside resistance mutation (Q151M): prevalence, associated resistance mutations and response to antiretroviral salvage treatment.

Quiros-Roldan E, Bertelli D, Signorini S, Airoldi M, Torti C, Moretti F, Carosi G. Quiros-Roldan E, et al. Microbios. 2001;106(414):137-45. Microbios. 2001. PMID: 11506064

10

[New strategies and new drugs in the salvage therapy for HIV infection].

Quirós-Roldán E, Torti C, Pan A, Carosi G. Quirós-Roldán E, et al. Med Clin (Barc). 2002 Feb 23;118(6):222-4. doi: 10.1016/s0025-7753(02)72341-5. Med Clin (Barc). 2002. PMID: 11864546 Review. Spanish. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

304 results

Search Page

Filters